Acne 

Actinic Keratosis 

Aesthetics

Anti-Aging

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Dry Cracked Skin

Hidradenitis Suppurativa

Impetigo

Inflamed Skin

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Surgery

Vitiligo

Wound Care

News

Media

2 Minute Drill

Around the Practice

Between The Lines

Case Based Peer Perspective

DermView

Editorial Board News

Expert Interviews

Expert Perspectives

Fellows Face Off

Frontline Forum

Inside the Clinic

Medical World News

Partner Perspectives

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Viewpoints

Webinars

Conferences

Conference Coverage

Conference Listing

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Image IQ

Interactive Tools

Job Board

Polls

Editorial Advisory Board

Partnerships

Subscribe

Print Subscription

eNewsletter

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

A poster presented at the 2023 ReV Virtual Conference explored the association between the 2 conditions.

Study Finds Association Between Vitiligo and Osteoporosis

, MD, PhD, is Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Chovatiya received his MD and PhD in immunology from Yale University. He completed his internship at Yale followed by residency and postdoctoral research fellowship at Northwestern, where he also served as Chief Resident. Dr. Chovatiya leads the Center for Eczema and Itch at Northwestern, and his clinical focus includes atopic dermatitis, eczema, chronic itch, and other chronic inflammatory skin disorders such as seborrheic dermatitis, psoriasis, urticaria, hidradenitis, and vitiligo. Dr. Chovatiya’s research focus includes the intersection of cutaneous immunology and inflammatory disease. He has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been recognized for his contributions as a speaker, researcher, and leader at national and international conferences.

Raj Chovatiya, MD, PhD, reviews a case of an adolescent patient with rapid changes in existing vitiligo.

Vitiligo Case Report: Rapid Onset of White Patches on Face, Neck, and Arms

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

Alan Irvine, MD, DSc: Atopic Dermatitis and the Biological Clock

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants. 

The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference  

Upadacitinib for Vitiligo Improves Patient Health-Related QoL After 24 Weeks  

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

BPDCN

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

View

With close to 60,000 new cases predicted for 2003, in terms of incidence melanoma is probably the fastest rising cancer in the United States. But even as the incidence of melanoma rises annually, the mortality rate has remained fairly stable.

Targeting Melanoma